












# Where is HIV now in the United States?









U=U


UNDETECTABLE UNTRANSMITTABLE

A PERSON LIVING WITH HIV WHO HAS AN UNDETECTABLE VIRAL LOAD DOES NOT TRANSMIT THE VIRUS TO THEIR PARTNERS.

The International AIDS Society is proud to endorse the U=U consensus statement of the Prevention Access Campaign.

### New HIV Diagnoses in San Francisco

No change since 2012 in the proportion of PLWH virally suppressed at 65%






# Standing on the Shoulders of Giants: SDART in Haiti and Ward 86 in SF


### Same Day ART

### Standard vs. Same-day ART



#### RAPID: Long-term Viral Suppression

2013-2017
Time From ART Start to First VL <200 Copies/mL and Percentage With VL <200 Copies/mL at Last VL Recorded, N=225



Coffey S. et al. AIDS, 2018.



### **CrescentCare Start Initiative (CCSI):**

Patients newly diagnosed with HIV are seen by a provider within 72 hours (optimally same-day) and provided 30 days of ART.

### **Early Intervention Services (EIS):**

Same protocol but patients contacted our clinic over 72 hours since diagnosis.

Range: 4 days – 25 years



### What Is CrescentCare?

- Started as an ASO in 1983.
- FQHC in 2014
- Primary care for adults, adolescents, and children
- Specialty care for people living with HIV
- Free HIV and STI testing through our sexual wellness clinic
- Community-wide/venue based HIV/STI Testing
- Dentistry
- PrEP clinic
- Transgender clinic
- Psychiatric services
- Addiction Medicine
- Case management, behavioral health, peer support, insurance enrollment assistance







### Total numbers

- Project started: 12/1/2016
- First CCSI Patient Seen: 12/6/2016
- Expanded to EIS: 12/21/2016

Total numbers: 368

- 227 CCSI
- 141 EIS



# Procedure/Methods

#### **Medical Provider Visit:**

- HIV Lifecycle, importance of adherence, U=U discussed
- Comorbidities assessed
- Physical Examination
- Provider option to not rx, alter medications if suspected resistance
- 30 day-supply of TAF/FTC/DTG
- DOT

#### **Post-Provider Visit:**

- Enroll in insurance programs
- Intake Labs obtained
- Social Work services for those with urgent needs



# CCSI/EIS Data Review

- Inclusion Criteria: clients enrolled into CCSI or EIS program from December 2016 through March 1, 2018.
- Lab values were then followed for an additional six months to develop a Continuum of Care.

### Total included for data review = 199

- 130 CCSI
- 69 EIS



### Data Review Presented Today


- 4 CCSI Patients referred but not linked and lost to follow up.
- All CCSI patients were started on ART on day of linkage

- 1 EIS patient was referred from the hospital but never linked – (She Passed away before ever linking)
- 1 EIS patients refused ART on day of diagnosis



# Age & Gender

- Median Age (CCSI) = 29 (1/3<sup>rd</sup> under 25)
- Median Age (EIS)= 29 (1/3<sup>rd</sup> under 25)





# Demographics

#### Race

Category	Race	%
CCSI	Black/AA	64.8%
CCSI	White	24%
	Latinx/Other	11.2%
EIS	Black/AA	70.6%
	White	20.6%
	Latinx/Other	8.8%

#### **HIV Risk Factor**

Category	Risk Factor	%
CCSI	Heterosexual Activity	38.1%
	MSM	57.9%
	PWID	4.0%
EIS	Heterosexual Activity	31.9%
	MSM	60.9%
	PWID	7.2%



### STIs with diagnosis

Category	Dx	%
CCSI	Syphilis	23.81%
	Gonorrhea or Chlamydia	26.03%
	Hepatitis B or C	4.76%
EIS	Syphilis	33%
	Gonorrhea or Chlamydia	24.1%
	Hepatitis B or C	9.1%



### Poverty Level, Insurance, Mental Health Diagnosis

### Federal Poverty Level

### Insurance at Baseline

Category	FPL	
CCSI	Under 100%	39.71%
EIS	Under 100%	36.62%


CCSI	Insured	48%
	Uninsured	52%
EIS	Insured	44%
	Uninsured	56%

### Mental Health Diagnosis by ICD 10 Code

CCSI	20%
EIS	33.3%



# Linkage time for CCSI (Hours from Knowledge of Diagnosis to Appointment with a Provider)





### **Baseline Data**

#### Baseline CD4


Category	CD4 Median	CD4% Median
CCSI	444 cells/mm <sup>3</sup>	25.7%
EIS	271 cells/mm³	18%


#### Baseline Viral Load

Category	Viral Load Median (copies/ml)
CCSI	42,600
EIS	70,150



# **Achieved Viral Suppression**







### Results

- 1. Time from Diagnosis to First Viral Load Suppression: CCSI
- 2. Time from Linkage to Care to First Viral Load Suppression: EIS

Category	Median (days)	Mean (days)
CCSI <sup>1</sup>	28	40.4
EIS <sup>2</sup>	27	51.28



#### CD4 Count, Viral Suppression, Transmitted Resistance

#### **CCSI:**


- All but two patients received TAF/FTC
   + DTG
- 118/126 genotypes were performed and reviewed.
- 22/118 (19%) with transmitted resistance
- 18 with NNRTI resistance
- 3/22 with M184V/I with two previously on PrEP
- 4/22 with multiple PI mutations including L90M
- All patients with transmitted resistance achieved viral suppression.
- No ART changes due to renal/hepatic toxicity

#### EIS:

- All but three patients received TAF/FTC + DTG
- 63/69 genotypes were performed
- 6/63 (9.5%) with transmitted resistance.
- 5 with NNRTI mutations
- 2/6 with M184V/I no previous PrEP exposure
- All patients with transmitted resistance achieved viral suppression
- No ART changes due to renal/hepatic toxicity




#### CCSI/EIS Continuum of Care December 1st 2016-March 1st 2018



- Retention in care: Defined as 2 provider visits separated by 3 months in past 12 months
- Viral Suppression: Less than 200 copies/ml and HIV RNA in past six months
- Median Enrollment 14 months (range: 6 months 21 months)

CCSI - 183 EIS - 108 Care Continuum: CCSI Cohort Compared to EIS Cohort

December 1<sup>st</sup>, 2016 – January 31<sup>st</sup>, 2019



Median Enrollment: 20 months (range: 6 months – 33 months)



### Key Facilitators of RAPID Intervention

- Same-day appointments
- Flexible provider scheduling (on call backup)
- ART-regimen preapproval prior to genotyping or lab testing
- Availability of ART starter packs
- Accelerated process for health insurance initiation
- Observation of first ART dose in clinic (recommended)
- Guarantee sustained access to ART



## Rapid Start Supports Equity

 AA men are more likely to have delays in ART initiation even after seeing a prescribing provider.<sup>1</sup>

 AA men and women are more likely to be prescribed a second line agent (most often a PI) when compared to white men and women.<sup>2</sup>


 No better demonstration of commitment to a community than same-day immediate access to a provider.



# **Concluding Comments**

- Both cohorts demonstrate that starting patients on the day of diagnosis or linkage, before labs are obtained, is highly accepted, safe and well-tolerated.
- Rapid entry/initiation improves
  - Time to viral suppression
  - Viral suppression at 12 months
  - Retention in care at 10–12 months
  - Survival at 12 months (international studies)
- Rapid entry/initiation is feasible in a variety of settings
- There are differences though in engagement between newly diagnosed patients (viral suppression 90%) and those who deferred immediate linkage (viral suppression 77%) P - 0.0071.
- Immediate ART leading to rapid viral suppression will be a key component of ending the HIV epidemic.







### **Thanks**

- Our Patients
- Fran Lawless and the New Orleans Mayor's Office
- New Orleans Regional Planning Council
- Katie Conner
- Pam Holm
- Nicholas Van Sickels
- Isolde Butler
- CrescentCare Staff